Recognition and Management of Hungry Bone Syndrome - A Case Report

A N Hisham, MS, E N Aina, MS, H Zanariah, MRCP*, Breast and Endocrine Surgical Unit, Departments of Surgery and *Medicine, Hospital Kuala Lumpur, 50586 Kuala Lumpur

Case Report

A 36 year-old Chinese man presented with generalised bone and joint pains for fifteen years. The pain had worsened progressively over the last six months and was associated with polyuria, polydipsia, malaise and weight loss. There was no previous history of renal calculi, pancreatitis or peptic ulcer disease. Clinical examination revealed an alert but anxious looking man. There was a palpable mass measuring 4 by 4cm at the left lower pole of thyroid gland.

Serum calcium was elevated to 2.98mmol/L (N: 2.1 - 2.6) whereas the serum phosphate was low 0.69mmol/L (N: 0.8 - 1.60). Serum alkaline phosphatase was 1607 IU/L (N: 53 - 128) and parathyroid hormone was markedly elevated to 804pgmol/l (N: 10 - 60). Full blood count, serum electrolytes and renal profile were within normal limits. Skeletal radiograph showed florid metabolic bone changes of hyperparathyroidism. Ultrasound of the neck showed a large solid homogenous mass in the left lower pole of thyroid gland. Neck computed tomography (CT) scan confirmed of a large mass without evidence of local invasion. A presumptive diagnosis of primary hyperparathyroidism most likely due to a left inferior parathyroid adenoma was made.

Preoperative preparation was aimed at controlling the hypercalcaemia. He was hydrated with 6 - 8L of saline infusion daily and was given subcutaneous calcitonin two weeks prior to surgery. Postoperative hungry bone syndrome was predicted due to extensive bone involvement, marked elevation of serum alkaline phosphatase and parathyroid hormone. Hence, calcitonin and dihydroxy-vitamin D3 (calcitriol) were instituted to reduce demineralisation of the bone. Although his bone pain resolved, the biochemical derangement remained unchanged (Fig. 1). However, when 60mg of intravenous bisphosphonate (disodium pamidronate) was added serum calcium level dropped further, whereas serum phosphate level normalised just before surgery. Serum alkaline phosphatase level also dropped after treatment (Fig. 2).

At surgery the parathyroid tumour was removed without much difficulty. The tumour weighed 15 grams and histological examination confirmed the diagnosis of parathyroid adenoma. As expected serum calcium dropped within first 48 hours of surgery to 1.8mmol/L and was associated with low serum phosphate of 0.43mmol/L (Fig.1). These biochemical indices were strongly suggestive of hungry bone syndrome. He was treated with intravenous calcium infusion, oral calcium
supplements and dihydroxy-vitamin D3. After three weeks serum calcium reached near normal levels whereas serum phosphate normalised within a week. Four weeks after surgery he was mildly hypocalcaemic but clinically asymptomatic.

We would like to emphasise the importance of appropriate preoperative management. A well-balanced approach is necessary to prevent preoperative fatal hypercalcaemic crisis and at the same time reduce the postoperative hypocalcaemic consequence of HBS. In most instances the metabolic derangement of HBS following successful surgery can be minimised or reduced by prophylactic preoperative treatment. This avoids prolonged and vigorous postoperative intravenous calcium infusion. However, no reports have examined the duration of the preoperative management and we would suggest at least two weeks preparation prior to surgical intervention. However, prolonged medical therapy is not always necessary or advantageous. It should be abandoned in favour of early operation if the patient’s condition is deteriorating with recalcitrant hypercalcaemia.

Preoperative treatment with dihydroxy-vitamin D3 (calcitriol) has been used but its effect is variable. It is important to note that despite treatment with dihydroxy-vitamin D3 and calcitonin, the occurrence of severe HBS has been documented. The preoperative management with inorganic phosphate has been abandoned because of lethal complications of pulmonary, soft tissue and intravascular calcium deposition.

HBS is characterised by prolonged and severe postoperative hypocalcaemia and hypophosphataemia as a result of extensive and accelerated remineralisation of bone following sudden decrease of parathyroid hormone. This syndrome should be anticipated when there is evidence of severe parathyroid bone disease with marked elevation of serum alkaline phosphatase and serum parathyroid hormone. Risk factors predicting the development of HBS include age, high levels of alkaline phosphatase, blood urea nitrogen and size of adenoma. The size of the adenoma is the most important predictive factor.

We would like to emphasise the importance of appropriate preoperative management. A well-balanced approach is necessary to prevent preoperative fatal hypercalcaemic crisis and at the same time reduce the postoperative hypocalcaemic consequence of HBS. In most instances the metabolic derangement of HBS following successful surgery can be minimised or reduced by prophylactic preoperative treatment. This avoids prolonged and vigorous postoperative intravenous calcium infusion. However, no reports have examined the duration of the preoperative management and we would suggest at least two weeks preparation prior to surgical intervention. However, prolonged medical therapy is not always necessary or advantageous. It should be abandoned in favour of early operation if the patient’s condition is deteriorating with recalcitrant hypercalcaemia.

Preoperative treatment with dihydroxy-vitamin D3 (calcitriol) has been used but its effect is variable. It is important to note that despite treatment with dihydroxy-vitamin D3 and calcitonin, the occurrence of severe HBS has been documented. The preoperative management with inorganic phosphate has been abandoned because of lethal complications of pulmonary, soft tissue and intravascular calcium deposition.

Hungry Bone Syndrome (HBS) following successful parathyroid surgery is not uncommon. In a study by Brasier et al, the incidence of HBS was 12.6% of 198 patients with primary hyperparathyroidism. Over the years it has been given less emphasis, as florid metabolic bone complications of hyperparathyroidism become a rarity.

HBS is characterised by prolonged and severe postoperative hypocalcaemia and hypophosphataemia as a result of extensive and accelerated remineralisation of bone following sudden decrease of parathyroid hormone. This syndrome should be anticipated when there is evidence of severe parathyroid bone disease with marked elevation of serum alkaline phosphatase and serum parathyroid hormone. Risk factors predicting the development of HBS include age, high levels of alkaline phosphatase, blood urea nitrogen and size of adenoma. The size of the adenoma is the most important predictive factor.

We would like to emphasise the importance of appropriate preoperative management. A well-balanced approach is necessary to prevent preoperative fatal hypercalcaemic crisis and at the same time reduce the postoperative hypocalcaemic consequence of HBS. In most instances the metabolic derangement of HBS following successful surgery can be minimised or reduced by prophylactic preoperative treatment. This avoids prolonged and vigorous postoperative intravenous calcium infusion. However, no reports have examined the duration of the preoperative management and we would suggest at least two weeks preparation prior to surgical intervention. However, prolonged medical therapy is not always necessary or advantageous. It should be abandoned in favour of early operation if the patient’s condition is deteriorating with recalcitrant hypercalcaemia.
deposition. Bisphosphonates on the other hand which are commonly used in treatment of malignancy-related hypercalcaemia and Paget's disease have been shown to be beneficial in treating hypercalcaemia in primary hyperparathyroidism and hungry bone syndrome.

Bisphosphonates are structurally related to pyrophosphates. They are safe and effective in controlling parathyroid-induced hypercalcaemia. They have been used in treating symptomatic patients who require re-operation, whilst allowing time for localisation studies and also as an alternative to surgery in elderly patients who are old or fragile. Furthermore, when force diuresis and other means of controlling hypercalcaemia fail, bisphosphonates provide optimal treatment.

The use of bisphosphonates in prevention of HBS has only recently been highlighted. Although the exact mechanism is not well understood, bisphosphonates are known to have a potent osteoclastic inhibitory effect on bone. Moreover, they have a transient inhibitory effect on mineralisation. It has been postulated that in bisphosphonate-induced inhibition of mineralisation, reduction of calcium uptake by bone occurs and therefore indirectly reduces the likelihood of acute postoperative hypocalcaemia.

It is interesting to note that preoperative bisphosphonate therapy not only reduces the severity of HBS but also shortens the course of postoperative calcium replacement following successful parathyroid surgery. In conclusion, this case report illustrates the need for careful perioperative management and emphasises the importance of anticipating HBS prior to surgical intervention.

Acknowledgements

The authors wish to thank Professor Dato' Khalid BAK for his assistance. We also thank the Director-General of Health Services, Malaysia, for his kind permission to publish this article.

**References**